Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Gastric cancer (GCa) is an aggressive malignancy, representing the third leading cause of cancer mortality worldwide. The poor prognosis of GCa can be associated with the prevalence of peritoneal metastasis (PM). Current international and national GCa treatment guidelines only recommend palliative t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2023-10, Vol.12 (20), p.6527
Main Authors: Jain, Anish J, Badgwell, Brian D
Format: Article
Language:English
Subjects:
Abdomen
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical medicine
Clinical trials
Development and progression
Gastric cancer
Health aspects
Hyperthermic intraperitoneal chemotherapy
Laparoscopy
Medical prognosis
Medical research
Medicine, Experimental
Metastasis
Methods
Multivariate analysis
Oncology, Experimental
Ostomy
Prognosis
Review
Stomach cancer
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer (GCa) is an aggressive malignancy, representing the third leading cause of cancer mortality worldwide. The poor prognosis of GCa can be associated with the prevalence of peritoneal metastasis (PM). Current international and national GCa treatment guidelines only recommend palliative treatment options for patients with PM. Since the 1980s there have been multiple single arm trials, randomized controlled trials, and metanalysis investigating the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced GCa, with or without PM. Results from these studies have been encouraging, with some large-volume centers even incorporating HIPEC into their treatment algorithms for patients with advanced GCa. Additionally, there are several ongoing trials that, when completed, will increase our understanding of the efficacy of CRS & HIPEC in patients with GCa metastatic to the peritoneum. Herein we review the current evidence, ongoing trials, consensus guidelines, and future considerations regarding the use of CRS & HIPEC in patients suffering from GCa with PM.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12206527